Basin Street Properties, a prominent real estate investment, development, and management firm, is pleased to announce emerging biotechnology firm BCD Bioscience has signed a 9,137 square foot lease at 2535 Capitol Oaks in Sacramento, California.

“We are very excited about our new location, it is perfect for our growth from a research company into a fiber ingredient supplier,” said Steven Watkins, CEO of BCD Bioscience. “2535 Capitol Oaks’ is also a very convenient location for our team members, who are spread throughout the Sacramento and Davis area, and it is obviously close to the airport for our visitors and partners.”

BCD Bioscience explores the natural world to discover new and diverse sources of carbohydrates – mining their unique chemistry and developing innovative applications for health and nutrition. BCD is a fast-paced, emerging biotechnology spinout from UC Davis creating ingredients for food and biopharmaceutical applications. BCD uses proprietary technology to create novel oligosaccharides from natural products, with a focus on producing ingredients that beneficially modulate the microbiome and immune function.

“BCD Bioscience offers such a unique innovative product in the health and nutrition industry,” said Scott Stranzl, Chief Portfolio Officer at Basin Street Properties. “We love to work with companies like BCD Bioscience that are on the cutting edge of science and finding new cures and solutions to improve our health and broader quality of life.”

Capitol Oaks Office Building is a Class A, four-story office building with 89,528 square feet. Located conveniently off Interstate 5 in the South Natomas sub-market, it features an extremely pedestrian-friendly campus with abundant free parking for both employees and clients. New capital improvements include HVAC, lobby, corridor, and signage upgrades. It further offers beautiful walking trails and the nearby riverwalk.

Scott Bennett of Colliers represented BCD Bioscience. Todd Eschelman and Jack Blackmon of Newmark represented Basin Street Properties.

ABOUT BCD BIOSCIENCE:

BCD Bioscience is creating the world’s first broad library of oligosaccharides with diverse natural structures and linking these structures to their functions as prebiotics and immunomodulators. BCD is using innovative technology to develop ingredients and therapies for better human and animal health both alone and in partnership with others.